REQUEST A DEMO
Total
USD $0.00
Search more companies

Novo Nordisk Pharma D.O.O. Beograd (Serbia)

Main Activities: Drugs and Druggists' Sundries Merchant Wholesalers
Full name: Novo Nordisk Pharma D.O.O. Beograd Profile Updated: September 30, 2025
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English Download a sample report

Novo Nordisk Pharma d.o.o. Beograd is the Serbian affiliate of Novo Nordisk, the global pharmaceutical company specializing in diabetes care, obesity treatment and biopharmaceutical therapies. The company's business segments include sales, marketing, medical support and distribution of prescription medicines, primarily insulin therapies, GLP 1 products and chronic disease treatments. It cooperates with healthcare institutions, pharmacies and medical professionals across Serbia. Key assets include a portfolio of internationally recognized pharmaceutical products and medical education programs. Strategically, Novo Nordisk Pharma d.o.o. focuses on improving access to innovative treatments and supporting long term chronic disease management in Serbia.

Headquarters
Milutina Milankovica 9 B
Belgrade; Belgrade;

Contact Details: Purchase the Novo Nordisk Pharma D.O.O. Beograd report to view the information.

Website: http://www.novonordisk.rs

Basic Information
Total Employees:
Purchase the Novo Nordisk Pharma D.O.O. Beograd report to view the information.
Registered Capital:
Purchase the Novo Nordisk Pharma D.O.O. Beograd report to view the information.
Financial Auditors:
Purchase the Novo Nordisk Pharma D.O.O. Beograd report to view the information.
Incorporation Date:
August 29, 2005
Key Executives
Purchase this report to view the information.
Chairman of the Supervisory Board
Purchase this report to view the information.
Member of the Supervisory Board
Purchase this report to view the information.
Director
Ownership Details
Purchase this report to view the information.
100%
Company Performance
Financial values in the chart are available after Novo Nordisk Pharma D.O.O. Beograd report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency RSD. Absolute financial data is included in the purchased report.
Net sales revenue
15.88%
Total operating revenue
15.88%
Operating profit (EBIT)
11.75%
EBITDA
12.01%
Net Profit (Loss) for the Period
16.1%
Total Assets
22.54%
Total Equity
29.14%
Operating Profit Margin (ROS)
-0.13%
Net Profit Margin
0%
Return on Equity (ROE)
-2.53%
Quick Ratio
0.07%
Cash Ratio
0.1%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?